期刊
CHEST
卷 141, 期 2, 页码 E89S-E119S出版社
ELSEVIER
DOI: 10.1378/chest.11-2293
关键词
-
资金
- National Heart, Lung, and Blood Institute [R13 HL104758]
- Bayer Schering Pharma AG
- Bristol-Myers Squibb
- Pfizer, Inc
- Canyon Pharmaceuticals
- sanofi-aventis US
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials. The article does not provide specific management recommendations but highlights important practical aspects of antiplatelet therapy, including optimal dosing, the variable balance between benefits and risks when antiplatelet therapies are used alone or in combination with other antiplatelet drugs in different clinical settings, and the implications of persistently high platelet reactivity despite such treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据